Collecting plasma samples from patients with head and neck squamous cell carcinoma
Official title: Prospective Collection of Plasma Samples From Patients Treated With Molecular Targeted Therapies for Squamous Cell Carcinoma of the Head and Neck
Run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · NCT02139020 · Data updated 2026-11-12
This study is collecting blood samples from patients with head and neck cancer to see if certain markers can help predict how well treatments like cetuximab will work for them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain Academic / other |
| Drugs / interventions | cetuximab, chemotherapy, radiation |
| Locations | 5 sites (Ottignies, Brabant Wallon and 4 other locations) |
| Status | Recruiting |
| Started | February 2013 |
| Main results expected | January 2033 |
| Study ends | January 2033 |
| Registry record updated | December 11, 2023 |
| Trial ID | NCT02139020 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with squamous cell carcinoma of the head and neck who are receiving targeted therapies, including cetuximab.
✕Probably not a fit
Patients with other types of head and neck cancers or those not treated with targeted therapies will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect plasma samples from patients diagnosed with squamous cell carcinoma of the head and neck at various stages: baseline, during treatment, and at progression. The collected samples will be utilized to investigate the potential of specific biomarkers in predicting the effectiveness of treatments, such as cetuximab and other targeted therapies. By analyzing these samples, researchers hope to gain insights into treatment responses and resistance mechanisms.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict treatment responses in patients, leading to more personalized and effective therapies.
How similar studies have gone: Other studies have shown promise in using plasma biomarkers to predict treatment responses in cancer, suggesting that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients treated with radiation therapy and cetuximab according to Bonner et al * patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. * patients treated with a molecular targeted agent as a part of a clinical study Exclusion Criteria: * patients with another type of head and neck cancer * patients non treated with targeted therapies
Where it's running
-
Clinique Saint-Pierre
Ottignies, Brabant Wallon, Belgium Recruiting -
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium Recruiting -
Centre Hospitalier Jolimont-Lobbes-Nivelles-Tubize
Haine-Saint-Paul, Belgium Recruiting -
CHU Liège
Liège, Belgium Recruiting -
Clinique et Maternité Sainte-Elisabeth
Namur, Belgium Recruiting
Study contacts
- Principal investigator: Jean-Pascal Machiels, MD, PhD — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Study coordinator: Jean-Pascal Machiels, MD, PhD
- Email: jean-pascal.machiels@uclouvain.be
- Phone: 0032 2 764
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ficerafusp alfa plus pembrolizumab before surgery for resectable head and neck squamous cell carcinoma
This trial will test whether giving ficerafusp alfa together with pembrolizumab before surgery helps people with PD‑L1–positive, resectable, high‑risk head and neck squamous cell carcinoma.
-
Cisplatin-related (Ear) Hearing Loss and Balance Issues in Head and Neck Cancer Patients
This observational study tests whether hearing loss, tinnitus, and balance problems occur in head and neck cancer patients treated with cisplatin chemoradiotherapy compared with those receiving only radiotherapy, including optional genetic tests for susceptibility.
-
Injecting a viral particle to treat head and neck cancer
This study is testing a new virus injection to see if it can help treat head and neck cancer in different groups of patients.
-
Understanding the mechanisms behind squamous cell carcinomas
This study is trying to learn more about squamous cell carcinoma by looking at samples from patients to see how certain markers and cells affect the disease and its treatment.
-
Neoadjuvant chemotherapy with a vaccine for HPV-related throat cancer
This study is testing if a new vaccine combined with standard chemotherapy can help people with HPV-related throat cancer live longer and avoid radiation treatment.
-
MRG003 vs cetuximab/methotrexate for RM-SCCHN after prior therapies
This trial tests whether MRG003 can help people with recurrent/metastatic squamous cell carcinoma of the head and neck who have already tried PD-1 inhibitors and platinum therapy by comparing it to cetuximab plus methotrexate as a later-line treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.